This was the “top news” category. Now the physician info category. It gets filtered out by the mechanism that sends emails to SGLs and others when there is a new post. It is also filtered out by the blogs on all pages except the Archive and Physician Info page.
Zanubrutinib vs Ibrutinib in Symptomatic WM: Final Analysis From the Randomized Phase III ASPEN Study
2023-08-04T08:31:19-04:00Quoting from the paper, published in ASCO's Journal of Clinical Oncology: "Extended follow-up results confirm improved long-term safety and tolerability of zanubrutinib compared with ibrutinib and support deeper, earlier, and more durable responses in patients with WM regardless of previous treatment or CXCR4 and MYD88 mutational statuses."